Q1. Mass Drug Administration (MDA) for lymphatic filariasis elimination in India uses which combination of drugs?
(a) Chloroquine and Primaquine
(b) DEC and Albendazole
(c) Ivermectin and Doxycycline
(d) Metronidazole and Mebendazole
Q2. Which of the following functions is NOT performed by the lymphatic system?
(a) Returning excess interstitial fluid to circulation
(b) Transporting oxygen to body tissues
(c) Supporting immune responses through lymphocyte activity
(d) Absorbing dietary lipids from the intestine
Q3. Indocyanine green lymphography is used to:
(a) Detect malignant tumours in lymph nodes
(b) Assess the functioning and congestion of lymphatic vessels
(c) Measure lymphocyte count in the bloodstream
(d) Identify autoimmune disorders of the lymphatic system
Q4. The WHO’s Global Programme to Eliminate Lymphatic Filariasis (GPELF) primarily aims to:
(a) Develop a vaccine against filarial worms
(b) Interrupt transmission and alleviate suffering through MDA and morbidity management
(c) Genetically modify mosquito vectors to reduce their population
(d) Introduce natural predators of mosquitoes in endemic regions
Q5. With reference to manual lymphatic drainage (MLD), which of the following statements is most accurate based on current scientific evidence?
(a) MLD is effective as a standalone curative treatment for lymphoedema
(b) MLD has proven cosmetic benefits validated by large-scale clinical trials
(c) MLD may support lymphatic flow but shows limited efficacy when used in isolation, and is best combined with compression and exercise
(d) MLD is contraindicated for all cancer survivors
ANSWERS
1: (b)
India’s MDA strategy uses Diethylcarbamazine (DEC) combined with Albendazole to interrupt filarial transmission.
2: (b)
Oxygen transport is exclusively a function of the cardiovascular system via haemoglobin in red blood cells. The lymphatic system does not carry oxygen.
3: (b)
Indocyanine green lymphography is a specialised imaging technique that visualises lymphatic flow and identifies areas of congestion or damage.
4: (b)
GPELF combines MDA to stop transmission with morbidity management and disability prevention (MMDP) to reduce the burden on those already affected.
5: (c)
Evidence supports MLD as a supplementary therapy within a multimodal approach, but not as an independent treatment with significant or lasting outcomes.